Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

ABSTRACT:

Background

No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab.

Methods

We performed an uncontrolled, single-group, multicenter, investigator-initiated study of adjuvant paclitaxel and trastuzumab in 406 patients with tumors measuring up to 3 cm in greatest dimension. Patients received weekly treatment with paclitaxel and trastuzumab for 12 weeks, followed by 9 months of trastuzumab monotherapy. The primary end point was survival free from invasive disease.

Results

The median follow-up period was 4.0 years. The 3-year rate of survival free from invasive disease was 98.7%

SUBMITTER: Tolaney SM 

PROVIDER: S-EPMC4313867 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature